Aug 2026· Theoretical and Natural Science· 0 citations
TL;DR
Study shows the non-rapid eye movement spindle and slow oscillation activity are predictive and non-invasive biomarkers for AD, and the disruption of spindle-SO coupling is associated with Aβ deposits of AD.
Abstract
Alzheimer's disease (AD) is becoming more common and putting serious pressure on global health. Current Amyloid-β (Aβ) deposition and tau protein hyperphosphorylation are two main biomarkers of AD. Clinical diagnostic approaches depend on invasive detection of amyloid-β (Aβ) deposition and tau protein hyperphosphorylation through cerebrospinal fluid (CSF) analysis, positron emission tomography (PET) imaging or blood-based biomarker (BBM) testing. Evidence showed by recent studies have identified that slow-wave-sleep spindle coupling as potential non-invasive biomarkers of neurodegeneration for AD patients. Yet, the causality between spindle disruption and cognitive decline remains unknown. This paper examines the evidences from human, rodent models, and nonhuman primate (NHP) models of recent studies. This study presents how slow wave-spindle coupling reflects prefrontal-hippocampal, thalamocortical function. And it evaluates the contributions of NHPs researches for understanding the causal mechanisms. The findings provide supportive evidence that slow-wave-spindle activity is a reliable marker of thalamocortical integrity and prefrontal-hippocampal function correlating with cognitive decline for AD. Study shows the non-rapid eye movement (NREM) spindle and slow oscillation (SO) activity are predictive and non-invasive biomarkers for AD. The disruption of spindle-SO coupling is associated with Aβ deposits of AD. This predictive biomarker of AD points toward future directions for early detection and clinical interventions. These findings enable standardized predictive detection, home-based electroencephalography (EEG) monitoring and closed-loop stimulation techniques that could strengthen the clinical translation.
A stratified approach based on amyloid status is essential for the optimal application of blood-based biomarkers in monitoring disease progression and evaluating therapeutic efficacy in future clinical trials and precision medicine.
Keun You Kim, Hyunsun Ham, E. Yoon et al.· The journal of prevention of...· 0 citations
Overall, the CCD biomarker landscape supports a multimodal approach integrating Aβ dysregulation, axonal injury, and glial activation, which will strengthen the translational value of CCD as a model for human dementia, accelerating discovery and therapeutic development across species.
Klysse Assumpção Barbosa, Heloísa Máximo Ribeiro, L. Benevenuto et al.· Veterinary research communic...· 0 citations
This study investigates the link between metabolic profiles and beta-amyloid load in AD in order to shed light on possible biomarkers for disease progression and uses ultra-high-performance liquid chromatography (UPLC) to investigate the correlation between baseline metabolic data and changes in amyloid PET scores.
Marjan Falahati, Elham Ramezannejad, Yosra Vaez-Gharamaleki et al.· Research Square· 0 citations
The authors critically appraise the current evidence supporting plasma phosphorylated tau at threonine 217 (p-tau217) as the leading BBM for AD, and highlight current limitations, unresolved challenges, and future perspectives for the integration of plasma biomarkers into routine clinical practice.
L. Gaetani, Giovanna Nardi, Lucilla Parnetti· Expert Review of Neurotherap...· 0 citations
In cognitively unimpaired older adults, elevated blood p-tau217 was linked to faster shrinkage in AD-specific brain regions, whereas NfL and GFAP were associated with more widespread atrophy, with NfL also associated with accelerated WMH accumulation.
Martina Valletta, D. L. Vetrano, E. J. Laukka et al.· Annals of Neurology· 0 citations
In biomarker-confirmed AD, NREM SP and SO activity are associated with CSF orexin concentrations and moderate associations between orexin and longitudinal cognitive and neuropsychiatric outcomes, independent of Aβ42 and tau.
Arsenio Páez, G. Piñol-Ripoll, A. Carnes-Vendrell et al.· Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.